

## IN THE CLAIMS

1. (currently amended) An immunogenic composition comprising:

an isolated Group B streptococcus (GBS) saccharide antigen selected from GBS serotype Ia, Ib, and III, and

at least two isolated GBS polypeptide antigens, ~~wherein the isolated GBS polypeptide antigens are selected from the group consisting of:~~ GBS 80 set forth as SEQ ID NO:2 ~~or~~[[,]] immunogenic fragments of ~~the~~ GBS 80 comprising at least 7 consecutive amino acids of SEQ ID NO:2[[,]] ~~and~~

~~GBS 91 set forth as SEQ ID NO:4;~~

~~immunogenic fragments of GBS 91 comprising at least 7 consecutive amino acids of SEQ ID NO:4;~~

~~GBS 104 set forth as SEQ ID NO:6;~~

~~immunogenic fragments of GBS 104 comprising at least 7 consecutive amino acids of SEQ ID NO:6;~~

~~GBS 147 set forth as SEQ ID NO:8;~~

~~immunogenic fragments of GBS 147 comprising at least 7 consecutive amino acids of SEQ ID NO:8;~~

~~GBS 173 set forth as SEQ ID NO:10;~~

~~immunogenic fragments of GBS 173 comprising at least 7 consecutive amino acids of SEQ ID NO:10;~~

~~GBS 276 set forth as SEQ ID NO:12;~~

~~immunogenic fragments of GBS 276 comprising at least 7 consecutive amino acids of SEQ ID NO:12;~~

~~GBS 305 set forth as SEQ ID NO:14;~~

~~immunogenic fragments of the GBS 305 comprising at least 7 consecutive amino acids of SEQ ID NO:14;~~

~~GBS 313 set forth as SEQ ID NO:16;~~

~~immunogenic fragments of the GBS 313 comprising at least 7 consecutive amino acids of SEQ ID NO:16;~~

~~GBS 322 set forth as SEQ ID NO:18 or [[,]] immunogenic fragments of the GBS 322 comprising at least 7 consecutive amino acids of SEQ ID NO:18[[,]]~~

~~GBS 328 set forth as SEQ ID NO:20;~~

~~immunogenic fragments of GBS 328 comprising at least 7 consecutive amino acids of SEQ ID NO:20;~~

~~GBS 330 set forth as SEQ ID NO:22;~~

~~immunogenic fragments of GBS 330 comprising at least 7 consecutive amino acids of SEQ ID NO:22;~~

~~GBS 338 set forth as SEQ ID NO:24;~~

~~immunogenic fragments of GBS 338 comprising at least 7 consecutive amino acids of SEQ ID NO:24;~~

~~GBS 358 set forth as SEQ ID NO:26;~~

~~immunogenic fragments of GBS 358 comprising at least 7 consecutive amino acids of SEQ ID NO:26;~~

~~GBS 361 set forth as SEQ ID NO:28;~~

~~immunogenic fragments of GBS 361 comprising at least 7 consecutive amino acids of SEQ ID NO:28;~~

~~GBS 404 set forth as SEQ ID NO:30;~~

~~immunogenic fragments of GBS 404 comprising at least 7 consecutive amino acids of SEQ ID NO:30;~~

~~GBS 656 set forth as SEQ ID NO:32;~~

~~immunogenic fragments of GBS 656 comprising at least 7 consecutive amino acids of SEQ ID NO:32;~~

~~GBS 690 set forth as SEQ ID NO:34;~~

~~immunogenic fragments of GBS 690 comprising at least 7 consecutive amino acids of SEQ ID NO:34;~~

~~GBS 691 set forth as SEQ ID NO:36; and~~

~~immunogenic fragments of GBS 691 comprising at least 7 consecutive amino acids of SEQ ID NO:34.~~

2. (withdrawn) The immunogenic composition of claim 1, wherein the at least two isolated GBS polypeptide antigens are polypeptides of a serotype II GBS bacterium.

3. (currently amended) The immunogenic composition of claim 1, wherein one of the at least two isolated GBS polypeptide antigens is the comprises GBS 80 set forth as SEQ ID NO:2 ~~or the immunogenic fragment of GBS 80.~~

4. (currently amended) The immunogenic composition of claim 3 which further comprises at least one additional GBS polypeptide antigen selected from the group consisting of:

- (1) GBS 91 set forth as SEQ ID NO:4,
- (2) GBS 104 set forth as SEQ ID NO:6,
- (3) GBS 147 set forth as SEQ ID NO:8,
- (4) GBS 173 set forth as SEQ ID NO:10,

- (5) GBS 276 set forth as SEQ ID NO:12,
- (6) GBS 305 set forth as SEQ ID NO:14,
- (7) GBS 313 set forth as SEQ ID NO:16,
- ~~(8) GBS 322 set forth as SEQ ID NO:18,~~
- (9) GBS 328 set forth as SEQ ID NO:20,
- (10) GBS 330 set forth as SEQ ID NO:22,
- (11) GBS 338 set forth as SEQ ID NO:24,
- (12) GBS 358 set forth as SEQ ID NO:26,
- (13) GBS 361 set forth as SEQ ID NO:28,
- (14) GBS 404 set forth as SEQ ID NO:30,
- (15) GBS 656 set forth as SEQ ID NO:32,
- (16) GBS 690 set forth as SEQ ID NO:34, and
- (17) GBS 691 set forth as SEQ ID NO:36,

wherein the at least one additional GBS polypeptide antigen is an isolated polypeptide.

5-6. (canceled)

7. (currently amended) The immunogenic composition of claim 1, wherein said composition further comprises a third isolated combination of at least three GBS polypeptide antigen antigens.

8. (currently amended) The immunogenic composition of claim 7, ~~wherein said combination~~ which comprises the GBS 80 set forth as SEQ ID NO:2 and the GBS 691 ~~GBS 694~~ set forth as SEQ ID NO:36.

9. (currently amended) The immunogenic composition of claim 7[[,]] which ~~wherein said combination~~ comprises the GBS 80 set forth as SEQ ID NO:2.

10. (currently amended) The immunogenic composition of claim 1, wherein at least one of the isolated GBS polypeptide ~~antigens~~ ~~antigen~~ is covalently linked to the GBS saccharide antigen.

11. (original) The immunogenic composition of claim 1, wherein said GBS saccharide antigen is covalently linked to a carrier protein.

12. (currently amended) The immunogenic composition of claim 11, wherein said carrier protein is selected from the group consisting of tetanus toxoid, diphtheria toxoid, *N. meningitidis meningitidis* outer membrane protein, heat shock protein, pertussis ~~pertussis~~ protein, protein D from *H. influenzae*, and toxin A or B from *C. difficile*.

13. (original) The immunogenic composition of claim 12, wherein said carrier protein is selected from the group consisting of tetanus toxoid and diphtheria toxoid.

14. (original) The immunogenic composition of claim 13, wherein said carrier protein is a diphtheria toxoid.

15. (original) The immunogenic composition of claim 14, wherein said diphtheria toxoid is CRM197.

16. (withdrawn) A method for the therapeutic or prophylactic treatment of GBS infection in an animal susceptible to GBS infection comprising administering to said animal a therapeutic or prophylactic amount of the immunogenic composition of claim 1.

17. (withdrawn—currently amended) A method for the manufacture of a medicament for raising an immune response against GBS comprising combining:

an isolated Group B streptococcus (GBS) saccharide antigen selected from GBS serotype Ia, Ib, and III; and

at least two isolated GBS polypeptide antigens, ~~wherein the isolated GBS polypeptide antigens are selected from the group consisting of:~~ GBS 80 set forth as SEQ ID NO:2 ~~or~~[[,]] immunogenic fragments of the GBS 80 comprising at least 7 consecutive amino acids of SEQ ID NO:2[[,]] and

~~GBS 91 set forth as SEQ ID NO:4,~~

~~immunogenic fragments of GBS 91 comprising at least 7 consecutive amino acids of SEQ ID NO:4,~~

~~GBS 104 set forth as SEQ ID NO:6,~~

~~immunogenic fragments of GBS 104 comprising at least 7 consecutive amino acids of SEQ ID NO:6,~~

~~GBS 147 set forth as SEQ ID NO:8,~~

~~immunogenic fragments of GBS 147 comprising at least 7 consecutive amino acids of SEQ ID NO:8,~~

~~GBS 173 set forth as SEQ ID NO:10,~~

~~immunogenic fragments of GBS 173 comprising at least 7 consecutive amino acids of SEQ ID NO:10,~~

~~GBS 276 set forth as SEQ ID NO:12,~~

~~immunogenic fragments of GBS 276 comprising at least 7 consecutive amino acids of SEQ ID NO:12,~~

~~GBS 305 set forth as SEQ ID NO:14,~~

~~immunogenic fragments of the GBS 305 comprising at least 7 consecutive amino acids of SEQ ID NO:14,~~

~~GBS 313 set forth as SEQ ID NO:16,~~

~~immunogenic fragments of the GBS 313 comprising at least 7 consecutive amino acids of SEQ ID NO:16;~~

~~GBS 322 set forth as SEQ ID NO:18 or [[,]] immunogenic fragments of the GBS 322 comprising at least 7 consecutive amino acids of SEQ ID NO:18[[,]]~~

~~GBS 328 set forth as SEQ ID NO:20;~~  
~~immunogenic fragments of GBS 328 comprising at least 7 consecutive amino acids of SEQ ID NO:20;~~

~~GBS 330 set forth as SEQ ID NO:22;~~  
~~immunogenic fragments of GBS 330 comprising at least 7 consecutive amino acids of SEQ ID NO:22;~~

~~GBS 338 set forth as SEQ ID NO:24;~~  
~~immunogenic fragments of GBS 338 comprising at least 7 consecutive amino acids of SEQ ID NO:24;~~

~~GBS 358 set forth as SEQ ID NO:26;~~  
~~immunogenic fragments of GBS 358 comprising at least 7 consecutive amino acids of SEQ ID NO:26;~~

~~GBS 361 set forth as SEQ ID NO:28;~~  
~~immunogenic fragments of GBS 361 comprising at least 7 consecutive amino acids of SEQ ID NO:28;~~

~~GBS 404 set forth as SEQ ID NO:30;~~  
~~immunogenic fragments of GBS 404 comprising at least 7 consecutive amino acids of SEQ ID NO:30;~~

~~GBS 656 set forth as SEQ ID NO:32;~~

~~immunogenic fragments of GBS 656 comprising at least 7 consecutive amino acids of SEQ ID NO:32;~~

~~GBS 690 set forth as SEQ ID NO:34;~~

~~immunogenic fragments of GBS 690 comprising at least 7 consecutive amino acids of SEQ ID NO:34;~~

~~GBS 691 set forth as SEQ ID NO:36; and~~

~~immunogenic fragments of GBS 691 comprising at least 7 consecutive amino acids of SEQ ID NO:34.~~

18. (currently amended) The immunogenic composition of claim 1, wherein the at least two isolated GBS polypeptide antigens are the GBS 80 set forth as SEQ ID NO:2 and the GBS 322 set forth as ~~represented by~~ SEQ ID NO:18.

19. (currently amended) The immunogenic composition of claim 18 wherein the isolated GBS saccharide antigen is ~~comprises~~ a GBS serotype 1a saccharide antigen.

20. (previously presented) The immunogenic composition of claim 18 further comprising a diphtheria toxoid.

21. (previously presented) The immunogenic composition of claim 20 wherein the diphtheria toxoid is CRM197.

22. (previously presented) The immunogenic composition of claim 19 further comprising a diphtheria toxoid.

23. (previously presented) The immunogenic composition of claim 22 wherein the diphtheria toxoid is CRM197.